AlphAIalphai — Financial news for AI agents
Investing.comMAR 132 min read$GRDN

Raymond James raises Guardian Pharmacy shares price target on vaccine program strength

Raymond James raised its price target on Guardian Pharmacy Services Inc. (NYSE:GRDN) to $40 from $35, maintaining an Outperform rating after strong fourth-quarter 2025 results. The company exceeded revenue and adjusted EBITDA estimates, driven by its successful flu vaccine program. Guardian Pharmacy also raised its 2026 guidance for adjusted EBITDA to $120-124 million, reflecting continued growth and improved operational execution, leading Truist Securities to also increase its price target.

Original reporting
Investing.com · Investing.com
Published Mar 13, 2026, 12:52 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 13, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Raymond James raises Guardian Pharmacy shares price target on vaccine program strength — source image
Source · Investing.com
Decision brief

The 30-second read

$GRDNBullishHigh
01

Why it matters

The analyst upgrade reflects confidence in the company's operational execution and growth prospects, likely attracting investor interest.

02

Market read

The news is highly relevant for investors interested in healthcare and vaccine-related stocks, with immediate trading implications.

03

What to watch

Potential regulatory hurdles or increased competition in vaccine services could impact future growth.

Timing: Immediate, given the recent upgrade and quarterly results.

Background

Guardian Pharmacy has demonstrated strong growth in vaccine services, notably its flu vaccine program, which contributed significantly to Q4 2025 performance.

Company-level read

Ticker impact

$GRDNBullishHigh confidence
Context

High relevance due to recent analyst upgrade and strong quarterly results.

Expected impact

Potential short-term increase of 5-10% in stock price following the upgrade, with sustained growth if operational targets are met.

Evidence & confidence

The upgrade by Raymond James, supported by strong quarterly results and raised guidance, indicates solid fundamentals and positive market sentiment, likely leading to upward price movement.

Market effects

Sector

Positive impact on the healthcare and life sciences sectors, especially vaccine-related companies.

Regional

Primarily US-focused, with potential ripple effects in global healthcare markets.

Global

Moderate, as the company operates mainly in the US, but vaccine program success has international implications.

Counterpoint

What could challenge this read

The positive outlook may be priced in already; any delays or setbacks in vaccine programs could lead to a correction.

Key entities

  • Company
    Guardian Pharmacy Services Inc.

    A healthcare company specializing in pharmacy and vaccine services.

  • Analyst Firm
    Raymond James

    Financial services firm providing investment research and ratings.

Read at source← All news

Related articles

AUG 8
$GRDNMed

Guardian Pharmacy Services Q2 Earnings Call Highlights

Guardian Pharmacy Services (GRDN) reported Q2 net income of $22.1M vs $8.8M a year earlier, including an $8.5M payer-dispute settlement recorded as other income. The company expects H2 revenue to fall low-single digits YoY due to IRA pricing reductions, with adjusted EBITDA margin stable in Q3 and seasonally higher in Q4. It also appointed Morris as COO and named a new CFO.

yahoo.com5 min
AUG 7
$GRDNMedAI 8/10

Guardian Pharmacy: Q2 Earnings Snapshot

Guardian Pharmacy Services Inc. (GRDN) reported Q2 profit of $21.9 million, or 34 cents per share. Adjusted earnings were 29 cents versus a Zacks-surveyed analyst average of 26 cents. Revenue was $351.8 million. The company forecast full-year revenue of $1.43 billion to $1.45 billion.

local3news.com2 min
AUG 6
$GRDNHigh

Guardian Pharmacy Services, Inc. (GRDN): Results of Operations and Financial Condition

Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d160709dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance ATLANTA, August 6, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”)

SEC EDGAR 8-K4 min
AUG 8
$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

fool.com6 min